

Lora Hamuro

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10061558/publications.pdf>

Version: 2024-02-01

8
papers

115
citations

1684188
5
h-index

1720034
7
g-index

8
all docs

8
docs citations

8
times ranked

171
citing authors

#	ARTICLE	IF	CITATIONS
1	Perspectives on Subcutaneous Route of Administration as an Immunogenicity Risk Factor for Therapeutic Proteins. <i>Journal of Pharmaceutical Sciences</i> , 2017, 106, 2946-2954.	3.3	58
2	Nivolumab Clearance Is Stationary in Patients With Resected Melanoma on Adjuvant Therapy: Implications of Disease Status on Time-Varying Clearance. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 1018-1027.	4.7	15
3	Developing a Natural History Progression Model for Duchenne Muscular Dystrophy Using the Six-Minute Walk Test. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2017, 6, 596-603.	2.5	13
4	Immunogenicity in Clinical Practice and Drug Development: When is it Significant?. <i>Clinical and Translational Science</i> , 2020, 13, 219-223.	3.1	11
5	Evaluating a Multiscale Mechanistic Model of the Immune System to Predict Human Immunogenicity for a Biotherapeutic in Phase 1. <i>AAPS Journal</i> , 2019, 21, 94.	4.4	10
6	Nivolumab exposure-response analysis for adjuvant treatment of melanoma supporting a change in posology. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021, 10, 748-759.	2.5	3
7	Exposure-Response Analysis to Support Nivolumab Once Every 4 Weeks Dosing in Combination with Cabozantinib in Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2022, 28, 1603-1613.	7.0	3
8	Changing the Drug Development and Therapeutic Paradigm with Biologic Drug Combinations and Bispecifics: How to Choose Between These Two Approaches?. <i>Clinical and Translational Science</i> , 0, , .	3.1	2